Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Caribou Biosciences Inc.

Citi analyst Yigal Nochomovitz maintained a Buy rating on Caribou Biosciences on May 8 and set a price target of $8.00. The company’s shares closed...

Caribou Biosciences (CRBU) Gets a Buy from Citi

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Caribou Biosciences (CRBU), Progyny (PGNY) and Evole...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRBU	$2.00	+1.52%	1.71M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRBU	$2.00	+1.5%	1.71M
3
4
5
6

CRBU

CRBU

Get Caribou Biosciences Inc. Data in Excel

Get Caribou Biosciences Inc. Data in Excel